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Abstract
Point-of-care (POC) tests offer potentially substantial beneﬁts for the management of infectious diseases, mainly by shortening the time
to result and by making the test available at the bedside or at remote care centres. Commercial POC tests are already widely avail-
able for the diagnosis of bacterial and viral infections and for parasitic diseases, including malaria. Infectious diseases specialists and
clinical microbiologists should be aware of the indications and limitations of each rapid test, so that they can use them appropriately
and correctly interpret their results. The clinical applications and performance of the most relevant and commonly used POC tests are
reviewed. Some of these tests exhibit insufﬁcient sensitivity, and should therefore be coupled to conﬁrmatory tests when the results
are negative (e.g. Streptococcus pyogenes rapid antigen detection test), whereas the results of others need to be conﬁrmed when positive
(e.g. malaria). New molecular-based tests exhibit better sensitivity and speciﬁcity than former immunochromatographic assays (e.g.
Streptococcus agalactiae detection). In the coming years, further evolution of POC tests may lead to new diagnostic approaches, such as
panel testing, targeting not just a single pathogen, but all possible agents suspected in a speciﬁc clinical setting. To reach this goal, the
development of serology-based and/or molecular-based microarrays/multiplexed tests will be needed. The availability of modern
technology and new microﬂuidic devices will provide clinical microbiologists with the opportunity to be back at the bedside, proposing
a large variety of POC tests that will allow quicker diagnosis and improved patient care.
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Introduction
Point-of-care (POC) tests are laboratory tests designed to
be used directly at the site of patient care, which may com-
prise physicians’ ofﬁces, outpatient clinics, intensive-care
units, emergency rooms, hospital laboratories, and even
patients’ homes. Such broad availability of diagnostic tests
needs systems that are accessible to personnel without spe-
ciﬁc laboratory medicine training, and allows quicker delivery
of results that directly inﬂuence the clinical decision [1]. Such
tests have become the standard of care for critically ill
patients, allowing bedside evaluation of vital parameters such
as blood gases or glycaemic control [2]. In the last 20 years,
the availability and use of POC tests have greatly increased
and expanded to all ﬁelds of medicine, so that a signiﬁcant
proportion of laboratory testing is currently conducted at
the point of care [1–3]. In the setting of infectious diseases,
most existing POC tests consist of immunoassays, namely
agglutination, immunochromatographic and immunoﬁltration
tests [4] (Table 1). Some non-immunological POC tests
based on nucleic acid detection are already available for a
few organisms, and might represent a major advance in the
coming years, with automation and generalization of these
technically demanding diagnostic approaches.
The decrease in analytical time in comparison with stan-
dard microbiological procedures offers potentially substantial
beneﬁts for the management of infectious diseases. Thus,
immediate identiﬁcation of a speciﬁc pathogen allows the use
of adequate empirical therapy, which has been shown to
improve the outcome in critically ill patients [5,6]. Similarly,
in cases of particular clinical syndromes such as lower respi-
ratory tract infections, POC tests may help to quickly iden-
tify situations where antibacterial therapy is relevant [7].
Conversely, the rapid diagnosis of viral infections such as
inﬂuenza can limit the prescription of antibacterial therapy
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and the need for additional tests [8]. Documentation in cere-
brospinal ﬂuid of enteroviral RNA has clearly modiﬁed the
management of a given patient with meningitis, in terms of
prescription of antibacterial agents, investigations, and dura-
tion of hospitalization [9]. Thus, POC tests might help to
limit the overuse of antibiotics, prevent the emergence of
resistance, and be cost-effective in reducing the charges asso-
ciated with diagnostic procedures and hospitalization. Fur-
thermore, the rapid documentation of a transmissible agent
at admission lowers the risk of its nosocomial transmission
[10]. In situations where immediate treatment is recom-
mended to interrupt further transmission and when patients
might not return for follow-up, such as for genital ulcers of
sexually transmitted diseases [11], the development of POC
tests may allow clinicians to better curtail the empirical ther-
apy, thus limiting toxicity and costs of unnecessary treat-
ments, and to obtain better compliance with treatment.
POC tests need easily obtained samples such as urine,
blood, saliva, or nasopharyngeal swabs. Although the use of
these tests does not require laboratory personnel, perfor-
mance is clearly linked to the experience of the operator
[12,13], which may inﬂuence the test’s accuracy. POC test
analytical errors have been described as relatively common,
and might impair patient care [14]. POC tests are usually
evaluated in comparison with standard microbiological
procedures, sometimes being performed concomitantly, and
their analytical characteristics are variable (Table 1). The
clinician should be fully aware of the limitations of each test,
and in taking the decision to use POC tests, must take into
account the clinical setting and patient characteristics such as
age, sex, comorbidities, and medical history. The traceability
and general accessibility of results might be impaired if inter-
facing with traditional informatics systems is not considered,
and this could lead to loss of data and difﬁculties with the
necessary quality controls [15].
In this review, we present the characteristics of a few
selected POC tests, illustrating the clinical impact of such
assays in the ﬁeld of clinical microbiology and infectious dis-
eases, and highlighting some of the limitations that clinicians
should take into account in order to use them appropriately.
Group A Streptococcal Rapid Test
Sore throat is a common reason for consulting paediatricians
and primary-care physicians. Most cases are of viral origin
[16]. Group A streptococcus is the most frequent aetiology
of bacterial pharyngitis, and may cause 5–10% of pharyngitis
cases in adults and up to 30% of pharyngitis cases in paediat-
ric patients [17]. Antibiotic therapy is mainly aimed at
TABLE 1. Indication and performances of commonly used point-of-care (POC) tests
Test/pathogen Type of test Sample Indication Performances Comment Ref.
Group A streptococcal
rapid test
EIA Pharyngeal swab Sore throat Sensitivity: 53–99%
Speciﬁcity: 62–100%
Conﬁrmation of negative swabs
with culture may be unnecessary
for adults
[19]
Pneumococcal antigen ICT Urine
(pleural ﬂuid, CSF)
Severe pneumonia
(empyema, meningitis)
Sensitivity: 66–70%
Speciﬁcity: 90–100%
Better sensitivity for severe
and bacteraemic pneumonias
[25–27]
Legionella antigen ICT Urine Severe pneumonia/risk factors
for legionellosis
Sensitivity: 76%
Speciﬁcity: 99%
Only serotype 1 reliably detected [34]
Group B streptococci POC
test–PCR
Vaginal swab Peripartum detection
of colonization
Sensitivity: 94–97%
Speciﬁcity: 96–100%
Performs better than late
antenatal screening
[41,42]
MRSA carriage
detection
POC
test–PCR
Nasal swab Risk factors, screening Sensitivity: 86–94%
Speciﬁcity: 93–95%
PCR-positive and culture-negative
samples consistent with many
circumstances
[57]
Clostridium difﬁcile
toxin detection
ICT Stool Antibiotic-associated
diarrhoea
Sensitivity: 49–80%
Speciﬁcity: 95–96%
Notably less sensitive than cultures [58,59]
Chlamydia antigen ICT Vaginal swab,
urine
Screening, suspicion of PID Sensitivity: 83%
Speciﬁcity: 99%
May lead to treat more infected
patients
[48]
Rapid malaria test ICT Blood Fever in returning traveller Sensitivity: 87–100%
Speciﬁcity: 52–100%
Sensitivity better for Plasmodium
falciparum (panmalarial tests)
[54,55]
Giardia lamblia rapid
diagnosis
EIA Stool Diarrhoea, especially for
returning travellers
Sensitivity: 58–98%
Speciﬁcity: 97–98%
May perform comparably to
microscopic examination of stools
[60,61]
RSV antigen ICT Nasopharyngeal
swab
Viral symptoms, especially
during the winter season
Sensitivity: 59–97%
Speciﬁcity: 75–100%
Lower viral load explains poorer
performance in adults
[62]
Inﬂuenza rapid test ICT Nasopharyngeal
swab
Flu-like symptoms Sensitivity: 20–55%
Speciﬁcity: 99%
Low sensitivity; probably not helpful
during outbreaks; lower in adults
[12,63]
Rotavirus antigen ICT Stool Diarrhoea (children) Sensitivity: 75–99%
Speciﬁcity: 95%
May be coupled with adenovirus
detection
[64,65]
Adenovirus antigen ICT Stool Diarrhoea Sensitivity: 22%
Speciﬁcity: 84%
Poor performance [65]
HIV rapid test ICT Blood (oral ﬂuid) Screening, prevention of
vertical transmission
Sensitivity: 99–100%
Speciﬁcity: 99–100%
Performance comparable to
standard tests
[66]
Enterovirus POC
test–PCR
CSF Meningitis Sensitivity: 97%
Speciﬁcity: 100%
Allows rapid discharge of
positive patients
[9,67]
CSF, cerebrospinal ﬂuid; EIA, enzyme immunoassay; HIV, human immunodeﬁciency virus; ICT, immunochromatographic test; MRSA, methicillin-resistant Staphylococcus aureus;
PID, pelvic inﬂammatory disease; RSV, respiratory syncytial virus.
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preventing acute rheumatic fever and suppurative complica-
tions such as peritonsillar abscesses [17]. Although clinical
scores have been used to estimate the probability of strepto-
coccal pharyngitis [18], microbiological assays are needed, as
clinical presentation alone does not allow clinicians to reliably
discriminate bacterial and viral aetiologies. Throat swab cul-
ture on a blood agar plate remains the reference standard.
Since the 1980s, several rapid tests targeting the group A
carbohydrate antigen of Streptococcus pyogenes have been
developed. The ﬁrst assays using agglutination techniques
were replaced by enzyme immunoassays and, more recently,
immunochromatographic tests, with a concomitant increase
in sensitivity [19] (Table 1). Despite the relative simplicity of
these tests, sensitivity has been linked to the experience of
the operator [13]. False-negative rapid test results are not
systematically explainable by low-level carriage of strepto-
cocci [20]. The excellent speciﬁcity, commonly higher than
95% [19], allows treatment to be started in the case of a
positive test result. Further beneﬁts of immediate-onset anti-
biotic therapy are an earlier decrease in infectivity and a
probable reduction in suppurative complications or at least in
their severity [17]. Thus, although the cost of immunochro-
matography may be slightly higher than that of culture, this
POC test is considered to be cost-effective. No further
decrease in the acute rheumatic fever rate is expected with
rapid tests, as antibiotic therapy may be safely delayed until
9 days after symptom onset [19]. The wide availability of
rapid streptococcal tests has led to a substantial reduction in
antibiotic prescriptions as compared with the period before
their implementation [21], thus potentially contributing to
prevention of the emergence of antibiotic resistance. Current
recommendations advise conﬁrmation of a negative test
result with agar plate cultures, at least for children [17]. The
lower frequency of streptococcal pharyngitis and the rarity of
acute rheumatic fever in adults may lead to avoid performing
culture in this subgroup of patients, at least when the pretest
probability of bacterial pharyngitis is low [18]. Not perform-
ing cultures implies a loss of follow-up for antibiotic resis-
tance, which is currently not relevant for penicillin, but is an
emerging issue for macrolides [22]. Moreover, the aetiological
agent of pharyngitis will not be identiﬁed if it is a less com-
mon agent, such as group B or group G streptococcus.
Pneumococcal Urinary Antigen Test
Community-acquired pneumonia (CAP) is a common disease,
and represents the most frequent infectious cause of mortal-
ity in industrialized countries. The aetiology of CAP fre-
quently remains undetermined, mainly because of the broad
differential diagnosis and the low yield of standard microbio-
logical tests (i.e. sputum examination and culture, and blood
cultures). Severe CAP generally justiﬁes a more extensive
attempt at aetiological diagnosis [23]. The availability of POC
tests may allow clinicians to safely restrict their initial empiri-
cal therapy and so help to prevent unnecessary antibiotic use
contributing to resistance.
Streptococcus pneumoniae is the most frequently docu-
mented agent of CAP, and may represent a major cause of
pneumonia of undetermined origin [23,24]. An immunochro-
matographic assay detecting the C-polysaccharide common
to the cell walls of all pneumococcal serotypes was approved
by the FDA in 1999. The availability of the result in 15 min
offers a diagnostic alternative, especially when good-quality
sputum cannot be obtained. The sensitivity of this assay was
investigated against standard microbiological cultures of
lower respiratory tract samples and blood cultures, and
ranges from 66% to 70% [25,26], increasing in a setting of
severe/bacteraemic pneumonia to 80–94% [25,27]. Although
a high speciﬁcity of 90–100% has been demonstrated [25–
27], as many as 21% of healthy children younger than
12 months of age present with a positive urinary antigen,
correlating with nasopharyngeal pneumococcal carriage [28].
As urinary antigen excretion may persist for up to 6 months
after a documented episode of pneumococcal pneumonia
[29], a previous pulmonary infection must be sought in the
medical history to interpret the assay. Although this urinary
antigen test will obviously not replace standard microbiologi-
cal tests, in particular for assessment of antibiotic resistance
of S. pneumoniae, the documentation of a pneumococcal
pneumonia with the use of this POC test may allow clinicians
to restrict empirical therapy [7]. The urinary antigen could
be particularly useful when sputum is not available or for
severe CAP, as it can detect as many as one-fourth more
cases than Gram staining [25]. Pneumococcal antigen detec-
tion may be applied with acceptable performance to other
clinical samples, such as pleural effusion or cerebrospinal
ﬂuid, where S. pneumoniae is also a frequent pathogen
[30,31].
Legionella Urinary Antigen Test
Legionella pneumophila was ﬁrst recognized in 1976 in the set-
ting of a localized major outbreak. Standard cultures for diag-
nosis of this fastidious organism usually need 2–7 days, and
seroconversion may take several weeks [32]. Soon after rec-
ognition of the organism, diagnostic tests based on speciﬁc
detection of a lipopolysaccharide portion of Legionella cell
wall antigen in urine became available [32]. The broad use of
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such assays transformed the diagnosis of the disease, allowing
rapid detection of the pathogen, as early as 1 day after onset
of symptoms. This easier diagnosis may contribute to the
observed global increase in the incidence of legionellosis:
cases detected by the urinary antigen increased from 15% in
1995 to 33% in 1998, and to more than 90% in 2006 [33].
Importantly, this assay only reliably detects serogroup 1,
which is responsible for about 90% of all cases in America
and Europe [32]. Performance of this test was evaluated in a
recent meta-analysis [34]. Although an excellent speciﬁcity of
99% has been demonstrated, the sensitivity of this POC test
is lower than that of lower respiratory tract culture, at
about 76%. Thus, in clinical practice, a negative urinary anti-
gen result does not deﬁnitively exclude an L. pneumophila
infection. Conversely, a positive test result is usually diagnos-
tic, despite possible prolonged antigen excretion for several
months, especially in immunosuppressed patients with a
longer time to defervescence [35]. Recent guidelines recom-
mend the use of this POC test in a setting of severe pneu-
monia and speciﬁc risk factors such as alcohol abuse and
recent travel [23]. A rapid aetiological diagnosis may
decrease mortality by allowing adequate initial treatment
[6,36], although coverage of Legionella is necessary for severe
CAP, even when the urinary test result is negative [23]. A
positive impact in lowering the case-fatality rate in the set-
ting of L. pneumophila outbreaks has also been suggested
[37].
Detection of Group B Streptococci
Group B streptococcal (GBS) disease is a leading cause of
neonatal morbidity and mortality; rectal and/or vaginal colo-
nization of the mother may lead to vertical transmission of
Streptococcus agalactiae to the newborn during labour [38].
Early-onset neonatal disease is efﬁciently prevented by intra-
partum antibiotics [39]. Although classical risk factors such
as intrapartum fever, preterm delivery and prolonged mem-
brane rupture have been recognized [38], the optimal
screening approach is still a matter of debate. Guidelines
from the CDC advise systematic screening during the late
antepartum period (35–37 weeks) [40]. Peripartum adminis-
tration of antibiotic prophylaxis is recommended for carriers.
A risk-based approach is reserved for unscreened women in
labour [39]. As colonization is often transient, the sensitivity
of late antenatal cultures remains inferior to that of screen-
ing during labour. Consequently, the majority of early-onset
GBS disease occurs in newborns of mothers with negative
antenatal cultures and no risk factors [41]. Furthermore,
preterm deliveries, which classically present a higher risk of
GBS disease, do not beneﬁt from this screening. Given the
potentially low compliance with antepartum screening and
difﬁculties with its practical application, there is obvious
interest in a POC test for the immediate peripartum period.
Rapid tests using antigen detection have been available for
years; none of them showed sufﬁcient sensitivity as com-
pared with concomitant culture to safely allow a therapeutic
decision at the time of delivery [42]. Automation of real-time
PCR-based assays progressively led to a broader availability
of rapid methods with a sensitivity close to 100% [41,42].
Thus, although the feasibility of broad implementation of
PCR-based POC tests has still to be demonstrated, they may
contribute to further reducing the incidence of early-onset
GBS neonatal disease. The common use of these new-gener-
ation POC tests will not completely replace culture, as anti-
biotic susceptibility testing will still be needed, at least for
patients with severe b-lactam allergy, for whom macrolides
and clindamycin represent the best treatment options.
Indeed, although group B streptococci are consistently sensi-
tive to penicillin, resistance to these alternative treatments is
increasing [43].
POC Test for Chlamydia trachomatis
Infection
C. trachomatis is the most common bacterial sexually trans-
mitted disease worldwide. Most infected patients remain
asymptomatic, and high rates of infection have been
observed in women from several European settings [44]. Sys-
tematic screening programmes or detection based on risk
factors may decrease disease transmission and prevent long-
term complications, which mainly include pelvic inﬂammatory
disease, subsequent infertility, ectopic pregnancy, and miscar-
riage [45]. A role in male infertility is also accepted [46].
Molecular ampliﬁcation tests replaced culture of urethral/cer-
vical swabs as the diagnostic reference standard because of
their higher sensitivity and better acceptability when per-
formed on urine samples [47]. Thus, the observed increasing
incidence might be, in part, a result of more efﬁcient screen-
ing [48]. However, molecular diagnosis remains expensive,
and the delay before results are available implies a second
visit for the initiation of treatment. This second appointment
may often be missed, leaving numerous infected patients
untreated. On the other side, the high frequency of asymp-
tomatic infections makes microbiological diagnosis necessary
before empirical therapy.
In this setting, a POC test would have a major impact,
allowing patients to receive diagnosis and treatment during
the same consultation. Previously developed immunoassay-
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based rapid tests had shown poor sensitivity relative to
nucleic acid ampliﬁcation tests [48]. Despite inferior perfor-
mance, rapid tests might paradoxically lead to the treatment
of more infected patients, in settings where the return rate
for results is low, and limit the risk of ongoing transmission
until treatment [49]. Recently, the availability of a new gener-
ation of rapid tests demonstrating higher sensitivity,
approaching that of PCR-based assays, brought hope for a
better yield of screening, both in industrialized and in low-
income countries [48]. Automation of current real-time PCR
assays [50] may lead to the future availability of new-genera-
tion, nucleic acid-based POC tests, allowing optimal manage-
ment of infected patient with a same-day screening strategy.
Malaria Rapid Tests
Malaria remains a leading cause of death among infectious
diseases worldwide, and one of the most severe causes of
fever for travellers returning from endemic areas. The clini-
cal presentation is notably protean, and key symptoms such
as fever and chills might be missing in a substantial propor-
tion of patients [51]. Thus, about 60% of cases are initially
misdiagnosed in North America [52]. Malaria leads to death
for about 1% of affected travellers, and many of these fatal
evolutions might have been prevented in non-immune sub-
jects, especially if treatment had been promptly initiated [51].
A diagnostic assay is therefore needed in the setting of the
broad differential diagnosis and the possibility of co-infec-
tions. Careful examination of Giemsa thick blood smears is
still considered to be the reference standard for malaria
diagnosis. Although it is relatively inexpensive, reliable diag-
nosis of malaria by microscopy needs skill and experience;
furthermore, it is rarely available in emergency rooms of
non-endemic countries, where expertise may be lacking, and
it may take a few hours for results to become available [53].
In recent years, rapid diagnostic techniques have been devel-
oped in response to these limitations. These immunochro-
matographic methods, introduced in the 1990s, target
antigens that are speciﬁc to one species, such as histidine-
rich protein 2 for Plasmodium falciparum, and/or pan-Plasmo-
dium antigens such as lactate dehydrogenase or aldolase [54]
(Fig. 1). When compared to microscopic evaluation as the
reference standard, these rapid tests, which deliver results in
about 15 min, show encouraging results. Sensitivity, which
may vary with the level of parasitaemia, is usually higher than
90%, especially for P. falciparum, the clinically most relevant
Plasmodium species [54,55]. Recent ﬁndings suggest that rapid
tests might perform better than microscopy in non-endemic
countries, with PCR-based diagnosis as the reference
standard [56]. The equal performance with ﬁnger sticks and
venous samples further supports their use as POC tests. As
histidine-rich protein 2 antigen may persist for more than
1 month after cure of malaria [54], the value of a positive
test result is difﬁcult to evaluate in hyperendemic settings or
in cases of low-grade parasitaemia in semi-immune patients.
False-positive test results are also classically described with
rheumatoid factor [54]. In non-endemic countries and for
the diagnosis of febrile returning travellers, false-positive
results remain rare. Conversely, the negative likelihood ratio
in such settings may reasonably exclude the diagnosis of
P. falciparum malaria in emergency rooms [55]. Nevertheless,
rapid tests do not allow reliable quantiﬁcation of antigen
amount, and so cannot replace microscopic evaluation for
the assessment of parasitaemia and therapeutic response
[54].
Conclusions and Future Prospects
Placing diagnostic tools directly in the hands of clinicians has
demonstrated signiﬁcant practical beneﬁts for many different
infectious diseases, and dramatically improved the diagnosis
of speciﬁc pathogens. Faster availability of results may lead
to better clinical outcomes, owing to immediate targeted
treatments and reduced use of combined empirical antibiotic
therapy, thus contributing to limiting the side effects and
potentially preventing the emergence of resistance. Thank to
ongoing developments, the impact of POC tests in clinical
practice will further increase within the coming years, espe-
cially in the management of pathogens that are poorly
detected with conventional microbiology approaches. More
FIG. 1. Three examples of a malaria rapid immunochromatographic
test, in which results are weakly positive (left), clearly positive (mid-
dle), and negative (right). C, positive control band; P, Plasmodium
species band; Pf, speciﬁc P. falciparum band.
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importantly than for classical diagnostic methods, knowledge
and consideration of POC test characteristics in a speciﬁc
clinical setting are mandatory to allow the rational use of
such assays (Fig. 2). As POC test use may occur in parallel
with conventional microbiology, demonstration of a clinically
favourable impact should be coupled with a strict evaluation
of the cost-effectiveness in the current setting of healthcare
resource rationalization.
POC tests evolved in parallel with the conventional diag-
nostic assays, and now also tend to include nucleic acid tech-
nology. Concomitantly, the deﬁnition of a POC test has
progressively broadened, to include tests not formally
designed for bedside use, but whose automation has allowed
the transfer of complex technology from classical laborato-
ries to sites of diagnosis and treatment, mirroring the former
spread of blood gase analysers in intensive-care units. The
eventual generalization of this new generation of POC tests
could potentially limit the impact of the operator on perfor-
mance, and enable the tests to achieve diagnostic yields clo-
ser to those standard microbiological assays. This
automation may overcome the previously common loss of
traceability, and allow the inclusion of POC test results in
databases consulted by clinicians, using computerized
connections.
In the coming years, further evolution of POC tests may
lead to new diagnostic approaches, such as panel testing, tar-
geting not just a single pathogen but all possible agents sus-
pected in a speciﬁc clinical setting. To achieve this goal, the
development of serology-based and/or molecular-based
microarrays/multiplexed tests will be needed. Technically,
the availability of modern technology, combining new micro-
ﬂuidic devices with improved tests, will soon offer the
opportunity to clinical microbiologists to be back at the bed-
side, proposing a new variety of POC tests that will allow
quicker diagnosis and improved patient care.
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